TLR2 and cancer: A polymorphism that causes a 22-bp deletion, known as TLR2 -196 to -174del, has been shown to influence the promoter activity of TLR2. This polymorphism has not only been associated with GC but also other inflammation-related cancers including gallbladder, bladder, prostate and cervical cancers [20], [21], [22], [23], [24].